EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-seizure gene therapy for focal cortical dysplasia

Amanda Almacellas Barbanoj, Robert T Graham, Benito Maffei, Jenna C Carpenter, Marco Leite, Justin Hoke, Felisia Hardjo, James Scott-Solache, Christos Chimonides, Stephanie Schorge, Dimitri M Kullmann iD, Vincent Magloire und 1 weitere

Brain · 01.02.2024 · 147 (2) · 542-553

DOI: 10.1093/brain/awad387 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 15.12.2023. Verfasst von Amanda Almacellas Barbanoj und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK. Hauptthemen laut MEDLINE: Focal Cortical Dysplasia, Epilepsy, Malformations of Cortical Development. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Wellcome Trust, MRF_.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Focal cortical dysplasias are a common subtype of malformation of cortical development, which frequently presents with a spectrum of cognitive and behavioural abnormalities as well as pharmacoresistant epilepsy. Focal cortical dysplasia type II is typically caused by somatic mutations resulting in mammalian target of rapamycin (mTOR) hyperactivity, and is the commonest pathology found in children undergoing epilepsy surgery. However, surgical resection does not always result in seizure freedom, and is often precluded by proximity to eloquent brain regions. Gene therapy is a promising potential alternative treatment and may be appropriate in cases that represent an unacceptable surgical risk. Here, we evaluated a gene therapy based on overexpression of the Kv1.1 potassium channel in a mouse model of frontal lobe focal cortical dysplasia. An engineered potassium channel (EKC) transgene was placed under control of a human promoter that biases expression towards principal neurons (CAMK2A) and packaged in an adeno-associated viral vector (AAV9). We used an established focal cortical dysplasia model generated by in utero electroporation of frontal lobe neural progenitors with a constitutively active human Ras homolog enriched in brain (RHEB) plasmid, an activator of mTOR complex 1. We characterized the model by quantifying electrocorticographic and behavioural abnormalities, both in mice developing spontaneous generalized seizures and in mice only exhibiting interictal discharges. Injection of AAV9-CAMK2A-EKC in the dysplastic region resulted in a robust decrease (∼64%) in the frequency of seizures. Despite the robust anti-epileptic effect of the treatment, there was neither an improvement nor a worsening of performance in behavioural tests sensitive to frontal lobe function. AAV9-CAMK2A-EKC had no effect on interictal discharges or behaviour in mice without generalized seizures. AAV9-CAMK2A-EKC gene therapy is a promising therapy with translational potential to treat the epileptic phenotype of mTOR-related malformations of cortical development. Cognitive and behavioural co-morbidities may, however, resist an intervention aimed at reducing circuit excitability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Focal Cortical DysplasiaEpilepsyMalformations of Cortical DevelopmentChildHumansMiceAnimalsTOR Serine-Threonine KinasesProtein Serine-Threonine KinasesSeizuresGenetic TherapyMammals

Stichwörter der Autor:innen

epilepsyfocal cortical dysplasiagene therapytranslation

Substanzen

TOR Serine-Threonine KinasesProtein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.
  • Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK.

ORCID-Profile: Dimitri M Kullmann, Gabriele Lignani

Förderung

  • Medical Research Council
  • Wellcome Trust
  • MRF_
  • Epilepsy Research UK

Zitieren

APA

Almacellas Barbanoj, A., Graham, R. T., Maffei, B., Carpenter, J. C., Leite, M., Hoke, J., Hardjo, F., Scott-Solache, J., Chimonides, C., Schorge, S., Kullmann, D. M., Magloire, V., & Lignani, G. (2024). Anti-seizure gene therapy for focal cortical dysplasia. Brain, 147(2), 542-553. https://doi.org/10.1093/brain/awad387

Vancouver

Almacellas Barbanoj A, Graham RT, Maffei B, Carpenter JC, Leite M, Hoke J, et al. Anti-seizure gene therapy for focal cortical dysplasia. Brain. 2024;147(2):542-553. doi:10.1093/brain/awad387

BibTeX
@article{AlmacellasBarbanoj2024,
  author = {Almacellas Barbanoj, Amanda and Graham, Robert T and Maffei, Benito and Carpenter, Jenna C and Leite, Marco and Hoke, Justin and Hardjo, Felisia and Scott-Solache, James and Chimonides, Christos and Schorge, Stephanie and Kullmann, Dimitri M and Magloire, Vincent and Lignani, Gabriele},
  title = {Anti-seizure gene therapy for focal cortical dysplasia},
  journal = {Brain},
  year = {2024},
  volume = {147},
  number = {2},
  pages = {542--553},
  doi = {10.1093/brain/awad387}
}
Kostenlos starten →